FISH Probes in Prenatal and Postnatal Diagnosis
The Fluorescence In Situ Hybridization (FISH) Probe Market is a cornerstone of modern molecular diagnostics, providing a powerful tool for the precise detection and localization of specific DNA or RNA sequences within cells and tissues. FISH probes are fluorescently labeled molecular tools that bind to a complementary target, allowing researchers and clinicians to visualize genetic abnormalities with exceptional clarity under a microscope. This technique is invaluable for identifying chromosomal abnormalities, gene amplifications, and translocations that are the hallmarks of various diseases.
The market for these advanced diagnostic tools is experiencing significant growth, fueled by the increasing global prevalence of cancer and genetic disorders. Valued at an estimated USD 1.21 billion in 2025, the market is projected to reach USD 1.69 billion by 2030, exhibiting a robust Compound Annual Growth Rate (CAGR) of 7.33%. This expansion is driven not only by the rising disease burden but also by continuous technological advancements that are making FISH more efficient, accurate, and accessible, particularly in the rapidly evolving fields of personalized medicine and oncology.
FAQs
How is FISH used for prenatal diagnosis? FISH is a rapid test used on amniotic fluid or chorionic villi samples to detect common chromosomal abnormalities like trisomy 21 (Down syndrome) and trisomy 18, providing a fast preliminary result while waiting for a full karyotype analysis.
What are the advantages of using FISH in this field? The primary advantage is speed. FISH provides results in a matter of hours, allowing for rapid decision-making for pregnant women at high risk for a chromosomal abnormality.